Cargando…
New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data
The assessment of the cardiovascular safety profile of any newly developed antihyperglycemic drug is mandatory before registration, as a meta-analysis raised alarm describing a significant increase in myocardial infarction with the thiazolidinedione rosiglitazone. The first results from completed ca...
Autores principales: | von Lewinski, Dirk, Kolesnik, Ewald, Wallner, Markus, Resl, Michael, Sourij, Harald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574229/ https://www.ncbi.nlm.nih.gov/pubmed/28894748 http://dx.doi.org/10.1155/2017/1253425 |
Ejemplares similares
-
Revisiting the Diabetes-Heart Failure Connection
por: Wallner, Markus, et al.
Publicado: (2018) -
SGLT2 Inhibitors and Their Antiarrhythmic Properties
por: Kolesnik, Ewald, et al.
Publicado: (2022) -
Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial
por: Benedikt, Martin, et al.
Publicado: (2023) -
Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial
por: Aziz, Faisal, et al.
Publicado: (2023) -
Timing of SGLT2i initiation after acute myocardial infarction
por: von Lewinski, Dirk, et al.
Publicado: (2023)